Our StoryBuilt from experience. Backed by science.
EM Radiance was founded by someone who lived the problem before she set out to solve it.
Emily Miller, CEO and Founder, has Ehlers-Danlos syndrome, a connective tissue disorder that affects how the skin heals, scars, and responds to treatment. Living with EDS means navigating a world where most skincare isn't made for skin that needs more: more support during recovery, more care around sensitivity, more intention behind every ingredient.
What she found in the market was a gap. Products that either felt clinical but didn't perform, or performed on paper but weren't built for complex skin. She decided to close that gap herself.
Why EM Radiance exists
EM Radiance was established to bring insight, knowledge, and real relief to inadequate skin restoration. The mission is straightforward: help people achieve the best version of their skin, not by overcomplicating skincare, but by getting the formulation right.
That means researching the finest ingredients, keeping formulas purposeful rather than padded, and validating every choice against both science and lived experience. From the first concept to packaging designed to protect ingredient integrity, every decision reflects the same standard of care.
What we're building toward
EM Radiance's signature Skin & Scar Cream, launching 2026, is the first expression of this vision. It is designed to improve the appearance of scars on the face and body, from surgical incisions to acne to injury, while actively supporting the skin barrier underneath.
We are committed to ongoing development, clinical insight, and data-backed validation as we continue to grow. The goal has never been a large product catalog, it's a focused, trustworthy line that practitioners and patients can rely on.
A cause that runs deeper
Emily's personal experience with EDS shaped not just the product, but the brand's values. EM Radiance actively supports the EDS Society and its mission to advance equitable, effective therapies for those living with Ehlers-Danlos syndrome. It's a reminder that behind every formulation decision is a real patient, and that better science leads to better outcomes for everyone.